Death and competition cause Exelixis dive on positive cabozantinib data in solid cancers
This article was originally published in Scrip
Executive Summary
Exelixis, which has put everything behind its lead anticancer product cabozantinib, closed 20% down on 6 June at $8.69 after the US company reported data from a Phase II trial showing that cabozantinib caused the deaths of six patients in a Phase II trial in patients with advanced solid tumours. The company now expects to begin a phase III study before the end of 2011.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.